Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$312.47
-0.7%
$281.36
$211.71
$329.72
$167.62B0.62.98 million shs1.97 million shs
Activision Blizzard, Inc. stock logo
ATVI
Activision Blizzard
$94.42
$93.80
$70.94
$94.57
$74.29B0.448.31 million shs1 shs
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
$116.30
$115.72
$60.03
$116.38
$26.63B1.032.50 million shsN/A
Microsoft Co. stock logo
MSFT
Microsoft
$420.21
-0.2%
$415.05
$309.45
$430.82
$3.12T0.8920.31 million shs15.35 million shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
0.00%+0.75%+18.92%+10.14%+38.86%
Activision Blizzard, Inc. stock logo
ATVI
Activision Blizzard
0.00%0.00%0.00%0.00%+21.22%
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
0.00%0.00%0.00%0.00%+15.71%
Microsoft Co. stock logo
MSFT
Microsoft
0.00%+1.32%+3.94%+4.00%+33.82%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amgen Inc. stock logo
AMGN
Amgen
4.8036 of 5 stars
2.34.03.33.93.72.51.9
Activision Blizzard, Inc. stock logo
ATVI
Activision Blizzard
0.5724 of 5 stars
1.00.02.52.10.61.71.3
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
N/AN/AN/AN/AN/AN/AN/AN/A
Microsoft Co. stock logo
MSFT
Microsoft
4.8542 of 5 stars
2.55.03.32.92.52.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.52
Moderate Buy$305.65-2.18% Downside
Activision Blizzard, Inc. stock logo
ATVI
Activision Blizzard
2.06
Hold$94.36-0.07% Downside
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
2.00
HoldN/AN/A
Microsoft Co. stock logo
MSFT
Microsoft
2.94
Moderate Buy$454.708.21% Upside

Current Analyst Ratings

Latest ATVI, AMGN, HZNP, and MSFT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/17/2024
Microsoft Co. stock logo
MSFT
Microsoft
Macquarie
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$460.00 ➝ $475.00
5/17/2024
Microsoft Co. stock logo
MSFT
Microsoft
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$450.00 ➝ $500.00
5/9/2024
Amgen Inc. stock logo
AMGN
Amgen
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$223.00 ➝ $235.00
5/3/2024
Amgen Inc. stock logo
AMGN
Amgen
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$284.00 ➝ $307.00
5/3/2024
Amgen Inc. stock logo
AMGN
Amgen
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$271.00 ➝ $310.00
5/3/2024
Amgen Inc. stock logo
AMGN
Amgen
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$332.00 ➝ $328.00
5/3/2024
Amgen Inc. stock logo
AMGN
Amgen
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$336.00 ➝ $355.00
5/3/2024
Amgen Inc. stock logo
AMGN
Amgen
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Equal Weight$230.00 ➝ $300.00
5/3/2024
Amgen Inc. stock logo
AMGN
Amgen
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
4/26/2024
Microsoft Co. stock logo
MSFT
Microsoft
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$480.00 ➝ $500.00
4/26/2024
Microsoft Co. stock logo
MSFT
Microsoft
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$450.00 ➝ $480.00
(Data available from 5/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$28.19B5.95$26.35 per share11.86$9.36 per share33.38
Activision Blizzard, Inc. stock logo
ATVI
Activision Blizzard
$8.71B8.53$3.38 per share27.91$24.59 per share3.84
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
$3.63B7.34$7.05 per share16.49$22.38 per share5.20
Microsoft Co. stock logo
MSFT
Microsoft
$211.92B14.74$11.73 per share35.82$34.06 per share12.34

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$6.72B$7.0044.6415.182.8112.74%156.21%10.82%8/1/2024 (Estimated)
Activision Blizzard, Inc. stock logo
ATVI
Activision Blizzard
$1.51B$2.7334.5924.092.6124.87%14.87%10.78%N/A
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
$521.48M$1.8762.1920.553.9612.02%20.46%11.52%N/A
Microsoft Co. stock logo
MSFT
Microsoft
$72.36B$11.5536.3831.882.2236.43%37.54%19.02%7/23/2024 (Estimated)

Latest ATVI, AMGN, HZNP, and MSFT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024Q1 2024
Amgen Inc. stock logo
AMGN
Amgen
$3.76$3.96+$0.20$8.13$7.45 billion$7.45 billion    
4/25/2024Q3 2024
Microsoft Co. stock logo
MSFT
Microsoft
$2.81$2.94+$0.13$2.94$60.86 billion$61.86 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$9.002.88%+10.01%128.57%13 Years
Activision Blizzard, Inc. stock logo
ATVI
Activision Blizzard
$0.991.05%N/A36.26%1 Years
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
N/AN/AN/AN/AN/A
Microsoft Co. stock logo
MSFT
Microsoft
$3.000.71%+10.11%25.97%22 Years

Latest ATVI, AMGN, HZNP, and MSFT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/12/2024
Microsoft Co. stock logo
MSFT
Microsoft
quarterly$0.750.72%5/15/20245/16/20246/13/2024
3/6/2024
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.253.25%5/16/20245/17/20246/7/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
11.96
1.42
0.98
Activision Blizzard, Inc. stock logo
ATVI
Activision Blizzard
0.17
4.66
4.66
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
0.48
4.27
4.09
Microsoft Co. stock logo
MSFT
Microsoft
0.17
1.24
1.23

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Activision Blizzard, Inc. stock logo
ATVI
Activision Blizzard
81.93%
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
80.37%
Microsoft Co. stock logo
MSFT
Microsoft
71.13%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.69%
Activision Blizzard, Inc. stock logo
ATVI
Activision Blizzard
1.08%
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
2.20%
Microsoft Co. stock logo
MSFT
Microsoft
0.03%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
26,700536.43 million532.73 millionOptionable
Activision Blizzard, Inc. stock logo
ATVI
Activision Blizzard
13,000786.80 million778.30 millionOptionable
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
2,115228.99 million223.96 millionOptionable
Microsoft Co. stock logo
MSFT
Microsoft
221,0007.43 billion7.43 billionOptionable

ATVI, AMGN, HZNP, and MSFT Headlines

Recent News About These Companies

Microsoft delivers an AI blow to Nvidia
Microsoft (NASDAQ:MSFT) Trading Down 0.4%
Microsoft (NASDAQ:MSFT) PT Raised to $475.00
10 Stocks to Build a Dividend Portfolio With

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Amgen logo

Amgen

NASDAQ:AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Activision Blizzard logo

Activision Blizzard

NASDAQ:ATVI
Activision Blizzard, Inc., together with its subsidiaries, develops and publishes interactive entertainment content and services in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through three segments: Activision, Blizzard, and King. It develops and distributes content and services on video game consoles, personal computers, and mobile devices, including subscription, full-game, and in-game sales, as well as by licensing software to third-party or related-party companies that distribute Activision and Blizzard products. The company also maintains a proprietary online gaming service, Battle.net that facilitates digital distribution of content, online social connectivity, and the creation of user-generated content. In addition, it operates esports leagues and offer digital advertising content; and provides warehousing, logistics, and sales distribution services to third-party publishers of interactive entertainment software, as well as manufacturers of interactive entertainment hardware products. The company's key product franchises include Call of Duty, World of Warcraft, Diablo, Hearthstone, Overwatch, Overwatch League, and Candy Crush. It serves retailers and distributors, including mass-market retailers, consumer electronics stores, discount warehouses, and game specialty stores through third-party distribution and licensing arrangements. The company was founded in 1979 and is headquartered in Santa Monica, California.
Horizon Therapeutics Public logo

Horizon Therapeutics Public

NASDAQ:HZNP
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Microsoft logo

Microsoft

NASDAQ:MSFT
Microsoft Corporation develops and supports software, services, devices and solutions worldwide. The Productivity and Business Processes segment offers office, exchange, SharePoint, Microsoft Teams, office 365 Security and Compliance, Microsoft viva, and Microsoft 365 copilot; and office consumer services, such as Microsoft 365 consumer subscriptions, Office licensed on-premises, and other office services. This segment also provides LinkedIn; and dynamics business solutions, including Dynamics 365, a set of intelligent, cloud-based applications across ERP, CRM, power apps, and power automate; and on-premises ERP and CRM applications. The Intelligent Cloud segment offers server products and cloud services, such as azure and other cloud services; SQL and windows server, visual studio, system center, and related client access licenses, as well as nuance and GitHub; and enterprise services including enterprise support services, industry solutions, and nuance professional services. The More Personal Computing segment offers Windows, including windows OEM licensing and other non-volume licensing of the Windows operating system; Windows commercial comprising volume licensing of the Windows operating system, windows cloud services, and other Windows commercial offerings; patent licensing; and windows Internet of Things; and devices, such as surface, HoloLens, and PC accessories. Additionally, this segment provides gaming, which includes Xbox hardware and content, and first- and third-party content; Xbox game pass and other subscriptions, cloud gaming, advertising, third-party disc royalties, and other cloud services; and search and news advertising, which includes Bing, Microsoft News and Edge, and third-party affiliates. The company sells its products through OEMs, distributors, and resellers; and directly through digital marketplaces, online, and retail stores. The company was founded in 1975 and is headquartered in Redmond, Washington.